Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Roche reports positive studies of MabThera given by subcutaneous injection
Imaging outcomes for trials of remyelination in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Treatment of acute transverse myelitis and its early complications.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Multiple sclerosis: an immune or neurodegenerative disorder?
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Biogen Reports Another Tecfidera PML Case
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Differential roles of microglia and monocytes in the inflamed central nervous system.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Rituximab Use in Pediatric Central Demyelinating Disease.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Pathological mechanisms in progressive multiple sclerosis.

Pages